Adjuvant treatment options for premenopausal women with hormone receptor–positive breast cancer now include endocrine therapy and ovarian function suppression (OFS) based on clinicopathologic characteristics that determine composite risk of recurrence.
Adjuvant Hormonal Therapy for Premenopausal Breast Cancer: Considerations for Ovarian Function Suppression
Understanding the role of the estrogen receptor (ER) in the pathogenesis of breast cancer has led to the development of treatment options that lead to reduced estrogen levels. In addition, the expression level of ER can serve as a prognostic indicator for disease recurrence and treatment response.
With the availability of approaches for preserving fertility and ovarian function, physicians should be prepared to discuss the impact of chemotherapy on fertility and ovarian function with patients newly diagnosed with breast cancer in order to personalize treatment plans based on patients’ goals. In the modern era, an increasing number of women are opting to delay pregnancy.
Measuring estradiol levels during ovarian function suppression (OFS) remains debatable. It can be argued that the assessment of estradiol levels is clinically irrelevant since general OFS can be achieved with the currently available approaches, and the outcomes of OFS trials are not based on estradiol levels. However, a variety of factors may lead to ovarian escape (OE).
Rationale and Evidence for Ovarian Function Suppression as a Fertility Preservation Strategy: Beyond the POEMS Trial
Despite the fact that 51% of patients with breast cancer have reported fertility concerns, evidence indicates that fertility preservation methods are underutilized.
Rationale and Evidence for Ovarian Function Suppression as a Strategy for Ovarian Function Preservation: The POEMS Trial and Beyond
Studies have demonstrated that at least half of patients undergoing treatment for breast cancer are concerned about potential infertility and demonstrate interest in becoming pregnant after the conclusion of their treatment. Even those not interested in pregnancy seek to avoid ovarian insufficiency and early menopause, which can negatively impact patients’ quality of life—an important treatment goal.
In the United States, 2 gonadotropin-releasing hormone (GnRH) agonists, goserelin and leuprolide, are widely available for ovarian function suppression (OFS) in patients with breast cancer. The ovarian-protective effects of GnRH agonists are mediated by downregulating GnRH receptors in the pituitary gland, which suppresses the release of luteinizing hormone and follicle-stimulating hormone.
Formulary Access and the Key Drivers for Decision-making From Institution Representatives: Why Do We Select Goserelin? Why Did We Select Leuprolide? Why Did We Select Triptorelin?
In Latin American countries, the onset of breast cancer is approximately 10 years earlier than in high-income countries. Moreover, the incidence rate of breast cancer in individuals aged <40 years is close to 11%, which is higher than the rates in developed regions such as the United States and the European Union. Additionally, most of these young women are diagnosed with advanced-stage disease.
A growing body of research has demonstrated that 5 to 10 years of adjuvant endocrine therapy (ET) plus ovarian function suppression (OFS) in patients with estrogen receptor (ER)-positive breast cancer reduces disease recurrence and mortality. However, despite this proven benefit, adverse events (AEs) associated with ET plus OFS may have a negative impact on patients’ quality of life.
In addition to the consideration of patient age, treatment selection for advanced breast cancer should include consideration of disease characteristics as outlined in evidence-based guidelines.
The Academy of Oncology Nurse & Patient Navigators (AONN+) Applauds the Centers for Medicare & Medicaid Services for Including Reimbursement for Oncology Patient Navigation in CY24 Medicare Physician Fee Schedule Proposal
Web Exclusives | July 20, 2023
In recognition of the recent announcement by the Centers for Medicare & Medicaid Services (CMS) proposing payment for community health integration services, the Academy of Oncology Nurse & Patient Navigators (AONN+) sees this opportunity as a key initiative to strengthen and accelerate the oncology navigation footprint in every community.
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Discordance Found Between Liquid and Tissue Biopsies in NGS in Patients With Non–Small Cell Lung Cancer at Disease Progression
A recently released study found a significant concordance rate drop between liquid and tissue biopsies via next-generation sequencing when patients had disease progression.
A recently published case study found sotorasib efficacious and safe as first-line therapy for non–small cell lung cancer harboring the KRAS G12C mutation.
A Canadian study found that next-generation sequencing identified more mutations, had a faster turnaround time, and was more cost-effective than single-gene testing when used in patients with non–small cell lung cancer.
A recent review of liquid biopsy studies found it useful in detecting circulating tumor DNA in patients with early and select advanced non–small cell lung cancer.
A recent review discussed multiple ongoing studies evaluating KRAS G12C inhibitors for the treatment of non–small cell lung cancer harboring the KRAS G12C mutation.
Oncology Nursing Considerations for Bispecific Antibodies in Multiple Myeloma: From Clinical Trial to Patient Bedside
Web Exclusives | April 20, 2023
Bispecific antibodies are unique antibody constructs that simultaneously bind 2 antigens, typically targeting an antigen on myeloma cells and a molecule on an immune cell. By using the patient’s immune system to destroy the malignant plasma cells, bispecific antibodies offer a promising treatment to overcome immunosuppression for patients with relapsing/refractory MM (RRMM).4
A recent study demonstrates liquid biopsy has high concordance to tissue biopsy in non–small-cell lung cancer, making it an acceptable first-line testing option.
Sotorasib Found to Have Promising Intracranial Activity in Patients with NSCLC with Brain Metastasis
A small study of patients with non–small-cell lung cancer with brain metastasis showed sotorasib had promising efficacy on brain lesions.
A recent retrospective analysis of patients with non–small-cell lung cancer harboring KRAS mutations found immune checkpoint inhibitors have benefit in first- and second-line treatment among KRAS subtypes.
Patients with KRAS G12C–Mutated NSCLC Experience a Short PFS When Treated with Docetaxel-Containing Regimens
A large retrospective chart review found a short median progression-free survival in patients with non–small-cell lung cancer harboring the KRAS G12C mutation who were treated with docetaxel with or without ramucirumab.
Biomarker testing is associated with improved overall survival in patients with advanced non–small-cell lung cancer, but disparities in access to testing persist.
A review of treatments and clinical studies for non–small-cell lung cancer harboring the KRAS G12C mutation finds encouraging overall survival results.
Palliative Care in Patients with Advanced NSCLC Varies Among Racial/Ethnic Groups and Insurance Providers
Palliative care is underused by Black and Hispanic/Latinx patients with advanced non–small-cell lung cancer.
Promising Results for Patients with Advanced NSCLC Treated with Flat-Dose Nivolumab plus Weight-Based Ipilimumab
Evaluation of flat-dose nivolumab plus weight-based ipilimumab in patients with advanced non–small-cell lung cancer and poorer prognosis demonstrates efficacy with a tolerable safety profile.
Web Exclusives | February 21, 2023
A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.
Page 1 of 9
Results 1 - 30 of 258
Results 1 - 30 of 258